Shanghai Yizhong Pharmaceutical Co Ltd Cash Flow Conversion Efficiency
Shanghai Yizhong Pharmaceutical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Shanghai Yizhong Pharmaceutical Co Ltd (688091) has a cash flow conversion efficiency ratio of 0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥21.03 Million ≈ $3.08 Million USD) by net assets (CN¥1.46 Billion ≈ $213.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Shanghai Yizhong Pharmaceutical Co Ltd (2017–2024)
Cash flow conversion efficiency of Shanghai Yizhong Pharmaceutical Co Ltd from 2017 to 2024. This chart illustrates how Shanghai Yizhong Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Shanghai Yizhong Pharmaceutical Co Ltd (688091) stock price for real-time trading data and today's change.
Shanghai Yizhong Pharmaceutical Co Ltd Cash Flow Conversion Ratio Explained
Shanghai Yizhong Pharmaceutical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Shanghai Yizhong Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Yizhong Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Also see Shanghai Yizhong Pharmaceutical Co Ltd (688091) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aurisco Pharmaceutical Co Ltd
SHG:605116
|
N/A |
|
Hunan Keli Motor Co Ltd
SHE:002892
|
0.044x |
|
Hisense Home Appliances Group Co. Ltd
F:GKE
|
0.212x |
|
Bristow Group Inc
NYSE:VTOL
|
-0.008x |
|
Alma Media Oyj
HE:ALMA
|
0.088x |
|
Bank Islam Malaysia Bhd
KLSE:5258
|
0.146x |
|
Hunan Oil Pump
SHG:603319
|
0.018x |
|
S.ENER.ELEC.SP.GDR REGS 1
F:ECEA
|
0.153x |
Annual Cash Flow Conversion Efficiency for Shanghai Yizhong Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Shanghai Yizhong Pharmaceutical Co Ltd from 2017 to 2024. Review Shanghai Yizhong Pharmaceutical Co Ltd free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.41 Billion ≈ $205.60 Million |
CN¥39.44 Million ≈ $5.77 Million |
0.028x | -52.50% |
| 2023-12-31 | CN¥1.46 Billion ≈ $214.35 Million |
CN¥86.55 Million ≈ $12.67 Million |
0.059x | -29.64% |
| 2022-12-31 | CN¥1.32 Billion ≈ $193.04 Million |
CN¥110.78 Million ≈ $16.21 Million |
0.084x | +302.36% |
| 2021-12-31 | CN¥1.18 Billion ≈ $172.02 Million |
CN¥-48.78 Million ≈ $-7.14 Million |
-0.041x | +50.00% |
| 2020-12-31 | CN¥243.51 Million ≈ $35.63 Million |
CN¥-20.21 Million ≈ $-2.96 Million |
-0.083x | +7.88% |
| 2019-12-31 | CN¥265.35 Million ≈ $38.83 Million |
CN¥-23.91 Million ≈ $-3.50 Million |
-0.090x | -78.92% |
| 2018-12-31 | CN¥212.18 Million ≈ $31.05 Million |
CN¥-10.68 Million ≈ $-1.56 Million |
-0.050x | +13.58% |
| 2017-12-31 | CN¥197.57 Million ≈ $28.91 Million |
CN¥-11.51 Million ≈ $-1.68 Million |
-0.058x | -- |
About Shanghai Yizhong Pharmaceutical Co Ltd
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was… Read more